keyword
MENU ▼
Read by QxMD icon Read
search

DCIS

keyword
https://www.readbyqxmd.com/read/28651115/ten-year-results-of-applying-an-original-scoring-system-for-addressing-adjuvant-therapy-use-after-breast-conserving-surgery-for-ductal-carcinoma-in-situ-of-the-breast
#1
Massimiliano Gennaro, Maria Carmen De Santis, Luigi Mariani, Salvatore Lo Vullo, Vera Cappelletti, Roberto Agresti, Umberto Cortinovis, Biagio Paolini, Serena Di Cosimo, Maria Luisa Carcangiu, Maria Grazia Daidone, Laura Lozza
PURPOSE: Although large-scale randomised clinical trials have established that radiotherapy (RT) - alone or combined with hormonal therapy (HT) - is effective in reducing the risk of ipsilateral breast tumour recurrence (IBTR), overall survival does not seem to be improved by adjuvant therapies. We sought to ascertain whether specific criteria can be adopted to avoid RT with an acceptable rate of IBTR after breast-conserving surgery (BCS) achieving tumour-free margins. PATIENTS AND METHODS: This non-randomised prospective study concerned the outcome of patients who underwent BCS for ductal carcinoma in situ (DCIS) and were prospectively assessed by means of an established scoring system based on width of free margins in association with age <40, presence of comedonecrosis, high grade, ER negativity and HER2 positivity, to orient the use of any adjuvant therapies...
June 23, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28650276/highlights-of-the-san-antonio-breast-cancer-symposium-2016
#2
John R Benson, Ismail Jatoi
The 39th annual San Antonio Breast Cancer Symposium (SABCS) was convened in San Antonio, Texas, on 9-13 December 2016. More than 7000 clinicians and scientists from around the world participated in the symposium which featured a range of presentations and keynote talks pertaining to breast cancer screening, prevention, locoregional and systemic therapies. This two-part report highlights a selection of important studies presented at this premier breast cancer event with Part 1 focusing onmetastatic breast cancer, extended endocrine therapy and the prognostic significance of BRCA1/2 gene mutations...
June 26, 2017: Future Oncology
https://www.readbyqxmd.com/read/28644994/is-the-systematic-circumferential-tumor-cavity-shaving-a-representative-sample-for-the-remaining-mammary-gland-about-75-cases
#3
H Bouzaiene, A Triki, M Ghalleb, M Chemlali, Z Benzarti, J Ben Hassouna, A Gammoudi, K Rahal
INTRODUCTION: The conservative surgery is more and more indicated for breast cancer. However, we still fear local recurrence which is mostly due to residual tumors?. Several techniques have been used to minimize theses residual tumors; one of them is the systematic circumferential tumor cavity shaving (SCTCS). METHODS: We sampled 75 female patients who had conservative surgery with positive shaved margins in the anatomopathology examination and to whom a complementary treatment with mastectomy have been decided...
June 20, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28637226/epidemiologic-risk-factors-for-in-situ-and-invasive-breast-cancer-among-postmenopausal-women-in-the-nih-aarp-diet-and-health-study
#4
Maeve Mullooly, Zeina G Khodr, Cher M Dallal, Sarah J Nyante, Mark E Sherman, Roni Falk, Linda M Liao, Jeffrey Love, Louise A Brinton, Gretchen L Gierach
Comparing risk factor associations between invasive breast cancers and possible precursors may further understanding of factors related to initiation versus progression. Accordingly, among 190,325 postmenopausal participants in the National Institutes of Health-AARP Diet and Health Study (1995-2011), we compared risk factor associations between incident ductal carcinoma in situ (DCIS: n = 1,453) and invasive ductal carcinomas (n = 7,525) and lobular carcinoma in situ (LCIS: n = 186) and invasive lobular carcinomas (n = 1,191)...
June 16, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/28634007/gene-expression-differences-between-ductal-carcinoma-in-situ-with-and-without-progression-to-invasive-breast-cancer
#5
Shusma C Doebar, Anieta M Sieuwerts, Vanja de Weerd, Hans Stoop, John W M Martens, Carolien H M van Deurzen
To understand the molecular alterations driving the progression of ductal carcinoma in situ (DCIS), we compared patients with pure DCIS and patients with DCIS and synchronous invasive breast cancer (IBC). Twelve patients with extensive pure DCIS were included as a representation of indolent lesions with limited invasive capacity. These cases were matched with 12 patients with a limited DCIS component and IBC, representing lesions with a high invasive potential. Matching included age and surrogate DCIS subtypes...
July 2017: American Journal of Pathology
https://www.readbyqxmd.com/read/28628731/response-to-her2-status-might-be-independent-determinant-associated-with-no-residual-disease-at-surgical-resection-in-patients-with-dcis
#6
Brittany L Murphy, James W Jakub
No abstract text is available yet for this article.
June 19, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28628656/ultrasound-guided-cable-free-13-gauge-vacuum-assisted-biopsy-of-non-mass-breast-lesions
#7
Jiwoon Seo, Sun Mi Kim, Mijung Jang, Bo La Yun, Soo Hyun Lee, Eun-Kyu Kim, Eunyoung Kang, So Yeon Park, Woo Kyung Moon, Hye Young Choi, Bohyoung Kim
PURPOSE: To compare the outcomes of ultrasound-guided core biopsy for non-mass breast lesions by the novel 13-gauge cable-free vacuum-assisted biopsy (VAB) and by the conventional 14-gauge semi-automated core needle biopsy (CCNB). MATERIALS AND METHODS: Our institutional review board approved this prospective study, and all patients provided written informed consent. Among 1840 ultrasound-guided percutaneous biopsies performed from August 2013 to December 2014, 145 non-mass breast lesions with suspicious microcalcifications on mammography or corresponding magnetic resonance imaging finding were subjected to 13-gauge VAB or 14-gauge CCNB...
2017: PloS One
https://www.readbyqxmd.com/read/28611201/relationship-of-the-breast-ductal-carcinoma-in-situ-immune-microenvironment-with-clinico-pathological-and-genetic-features
#8
Shona Hendry, Jia-Min B Pang, David Byrne, Sunil R Lakhani, Margaret C Cummings, Ian G Campbell, G Bruce Mann, Kylie L Gorringe, Stephen B Fox
The immune microenvironment of breast ductal carcinoma in situ (DCIS) has yet to be fully explored, and the relationship of immune cells to genetic features of DCIS is unknown. <br /><br />Experimental Design: We quantified tumour associated lymphocytes (TILs) and evaluated PD-L1 protein levels by immunohistochemistry in a cohort of pure DCIS (138 and 79 cases respectively), some of which had copy number (n=55) and mutation data (n=20). <br /><br />Results: TILs were identified in the stroma surrounding DCIS (119/138, 86%) and present at a median TIL score of 5% (range 0-90%)...
June 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28611039/chemoprevention-uptake-among-women-with-atypical-hyperplasia-and-lobular-and-ductal-carcinoma-in-situ
#9
Meghna S Trivedi, Austin M Coe, Alejandro Vanegas, Rita Kukafka, Katherine Crew
Women with atypical hyperplasia (AH) and lobular or ductal carcinoma in situ (LCIS/DCIS) are at increased risk of developing invasive breast cancer. Chemoprevention with selective estrogen receptor modulators or aromatase inhibitors can reduce breast cancer risk; however, uptake is estimated to be less than 15% in these populations. We sought to determine which factors are associated with chemoprevention uptake in a population of women with AH, LCIS, and DCIS. Women diagnosed with AH/LCIS/DCIS between 2007 and 2015 without a history of invasive breast cancer were identified (n=1719)...
June 13, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28610472/incidental-breast-carcinoma-in-reduction-mammoplasty
#10
Michaël Huysmans, Marc Bronckaers, Charlotte Schillebeeckx, Dirk Servaes
AIM: The objective of this study was to analyze the incidence and treatment options of occult cancer or atypical lesions found in the histopathological examination of reduction mammoplasty (RM) specimens. The role of preoperative mammography and systematic histopathological examination are discussed. METHODS: We performed a retrospective single-center database review of all patients who underwent a RM between January 2005 and December 2014. Preoperative examination, histopathological findings and follow-up were documented...
June 13, 2017: Acta Chirurgica Belgica
https://www.readbyqxmd.com/read/28608028/incidence-and-treatments-of-dcis-in-octogenarians-grade-matters
#11
Erin P Ward, Anna Weiss, Sarah L Blair
PURPOSE: The purpose of this study is to better characterize the current incidence and treatment patterns of DCIS in women greater than 80 years of age (>80) and to evaluate the effect of grade on treatment efficacy. METHODS: Retrospective observational study of women diagnosed with single primary DCIS from 2000 to 2012 in SEER. Statistics including incidence, multivariable Cox proportional hazards model and subset analysis were performed. RESULTS: 42,899 female patients with DCIS were identified, 2566 (5...
June 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28604763/proline-rich-homeodomain-protein-prh-hhex-is-a-suppressor-of-breast-tumour-growth
#12
R M Kershaw, D Roberts, J Wragg, A M Shaaban, E Humphreys, J Halsall, L Price, R Bicknell, K Gaston, P-S Jayaraman
Breast tumours progress from hyperplasia to ductal carcinoma in situ (DCIS) and invasive breast carcinoma (IBC). PRH/HHEX (proline-rich homeodomain/haematopoietically expressed homeobox) is a transcription factor that displays both tumour suppressor and oncogenic activity in different disease contexts; however, the role of PRH in breast cancer is poorly understood. Here we show that nuclear localization of the PRH protein is decreased in DCIS and IBC compared with normal breast. Our previous work has shown that PRH phosphorylation by protein kinase CK2 prevents PRH from binding to DNA and regulating the transcription of multiple genes encoding growth factors and growth factor receptors...
June 12, 2017: Oncogenesis
https://www.readbyqxmd.com/read/28589368/reassessing-risk-models-for-atypical-hyperplasia-age-may-not-matter
#13
REVIEW
Emanuele Mazzola, Suzanne B Coopey, Molly Griffin, Fernanda Polubriaginof, Julliette M Buckley, Giovanni Parmigiani, Judy E Garber, Barbara L Smith, Michele A Gadd, Michelle C Specht, Anthony Guidi, Kevin S Hughes
PURPOSE: The aim of this study was to investigate the influence of age at diagnosis of atypical hyperplasia ("atypia", ductal [ADH], lobular [ALH], or severe ADH) on the risk of developing subsequent invasive breast cancer or ductal carcinoma in situ (DCIS). METHODS: Using standard survival analysis methods, we retrospectively analyzed 1353 women not treated with chemoprevention among a cohort of 2370 women diagnosed with atypical hyperplasia to determine the risk relationship between age at diagnosis and subsequent breast cancer...
June 6, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28570750/epithelial-mesenchymal-transition-inducer-snail1-and-invasive-potential-of-intraductal-breast-cancer
#14
Bartlomiej Szynglarewicz, Piotr Kasprzak, Piotr Donizy, Przemyslaw Biecek, Agnieszka Halon, Rafal Matkowski
BACKGROUND AND OBJECTIVES: Transcription factor Snail1 is a key inducer of epithelial-mesenchymal transition (EMT), a biological process implicated in the cancer progression and metastasis. The aim of the study was to investigate Snail1 expression in DCIS found on breast biopsy and assess its predictive value for the final invasion. METHODS: A total of 209 patients with histologically diagnosed pure DCIS entered the study. Snail1 reactivity was evaluated with immunohistochemistry in tumor tissue from stereotactic vacuum-assisted biopsy of suspicious microcalcifications...
June 1, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28567637/comparison-of-her2-amplification-status-among-breast-cancer-subgroups-offers-new-insights-in-pathways-of-breast-cancer-progression
#15
Kathleen Lambein, Mieke Van Bockstal, Lies Vandemaele, Rudy Van den Broecke, Veronique Cocquyt, Sofie Geenen, Hannelore Denys, Louis Libbrecht
Although the prognostic and predictive significance of human epidermal growth factor receptor 2 (HER2) in invasive breast cancer is well established, its role in ductal carcinoma in situ (DCIS) remains unclear. Reports on combined evaluation of both HER2 protein expression and HER2 amplification status in pure DCIS and DCIS adjacent to invasive ductal carcinoma (i.e., admixed DCIS) are scarce. In this study, immunohistochemistry and fluorescence in situ hybridization (FISH) were used to assess HER2 status in 72 cases of pure DCIS, 73 cases of DCIS admixed with invasive ductal carcinoma (IDC), and 60 cases of pure IDC...
May 31, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28567547/breast-mr-imaging-for-the-assessment-of-residual-disease-following-initial-surgery-for-breast-cancer-with-positive-margins
#16
Julia Krammer, Elissa R Price, Maxine S Jochelson, Elizabeth Watson, Melissa P Murray, Stefan O Schoenberg, Elizabeth A Morris
OBJECTIVES: To determine the accuracy of post-operative MR in predicting residual disease in women with positive margins, emphasizing the size thresholds at which residual disease can be confidently identified. METHODS: This IRB-approved HIPAA-compliant retrospective study included 175 patients with MR after positive margins following initial surgery for breast cancer. Two expert readers independently re-evaluated MR images for evidence of residual disease at the surgical cavity and multifocal/multicentric disease...
May 31, 2017: European Radiology
https://www.readbyqxmd.com/read/28559459/tamoxifen-acceptance-and-adherence-among-patients-with-ductal-carcinoma-in-situ-dcis-treated-in-a-multidisciplinary-setting
#17
Lindsey C Karavites, Anna K Kane, Shruti Zaveri, Yanfei Xu, Irene Helenowski, Nora Hansen, Kevin P Bethke, Laura J Rasmussen-Torvik, Seema A Khan
Tamoxifen and other endocrine agents have proven benefits for women with ductal carcinoma in situ (DCIS) but low patient acceptance is widely reported. We examined factors associated with tamoxifen acceptance and adherence among DCIS patients who received a recommendation for therapy in a multidisciplinary setting. <p>Using our institutional database, we identified women diagnosed with DCIS, 1998-2009 who were offered tamoxifen. We recorded data on demographics, tumor and therapy variables, tamoxifen acceptance, and adherence to therapy for > 4 years...
May 30, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28558007/the-clinical-significance-of-accompanying-nme-on-preoperative-mr-imaging-in-breast-cancer-patients
#18
Hye Mi Gweon, Joon Jeong, Eun Ju Son, Ji Hyun Youk, Jeong-Ah Kim, Kyung Hee Ko
PURPOSE: To investigate the significance of accompanying NME in invasive ductal carcinoma (IDC) on preoperative MR imaging and assess the factors affecting the significance. METHODS: Between January 2015 and February 2016, 163 consecutive patients with IDC who underwent preoperative MR imaging and subsequent surgery were enrolled and reviewed. Index cancer mass size and total extent with accompanying NME on MR images was measured and compared with pathologic size...
2017: PloS One
https://www.readbyqxmd.com/read/28552797/hospital-organizational-factors-affect-the-use-of-immediate-breast-reconstruction-after-mastectomy-for-breast-cancer-in-the-netherlands
#19
K Schreuder, A C M van Bommel, K M de Ligt, J H Maduro, M T F D Vrancken Peeters, M A M Mureau, S Siesling
OBJECTIVES: Significant hospital variation in the use of immediate breast reconstruction (IBR) after mastectomy exists in the Netherlands. Aims of this study were to identify hospital organizational factors affecting the use of IBR after mastectomy for ductal carcinoma in situ (DCIS) or invasive breast cancer (BC) and to analyze whether these factors explain the variation. MATERIALS AND METHODS: Patients with DCIS or primary invasive BC treated with mastectomy between 2011 and 2013 were selected from the national NABON Breast Cancer Audit...
May 24, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28540335/ny-eso-1-expression-in-dcis-a-new-predictor-of-good-prognosis
#20
R Charles Coombes, Otavia L Caballero, Sami Shousha, Sadaf Ghaem-Maghami, Laura Woodley-Barker, Charlotte S Wilhelm-Benartzi, A Munro Neville
BACKGROUND: At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC. RESULTS: 14 of 42 (33%) of patients developed invasive breast cancer during the follow up period...
March 2017: Oncoscience
keyword
keyword
24526
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"